CN Patent

CN119192266A — 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途

Assigned to Sage Therapeutics Inc · Expires 2024-12-27 · 1y expired

What this patent protects

本文中提供根据式(I)和(III)的3,3‑二取代的19‑去甲甾族化合物，其中R 1 、R 2 、R 3 、R 3’ 、R 4 、R 6a 、R 6a 、R 11a 和R 11b 如本文中所定义。预期本发明的化合物对于多种CNS相关病症的预防和治疗，例如睡眠障碍、心境障碍、失眠症、焦虑、抑郁症、创伤性脑损伤(TBI)、应激和癫痫的治疗是有用的。

USPTO Abstract

本文中提供根据式(I)和(III)的3,3‑二取代的19‑去甲甾族化合物，其中R 1 、R 2 、R 3 、R 3’ 、R 4 、R 6a 、R 6a 、R 11a 和R 11b 如本文中所定义。预期本发明的化合物对于多种CNS相关病症的预防和治疗，例如睡眠障碍、心境障碍、失眠症、焦虑、抑郁症、创伤性脑损伤(TBI)、应激和癫痫的治疗是有用的。

Drugs covered by this patent

Patent Metadata

Patent number
CN119192266A
Jurisdiction
CN
Classification
—
Expires
2024-12-27
Drug substance claim
No
Drug product claim
No
Assignee
Sage Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.